At EBR, we are working to revolutionize cardiac rhythm management. Founded in Silicon Valley in 2003, the company focuses on blending clinical insights with technological ingenuity to overcome the limitations of conventional cardiac resynchronization therapy (CRT).
The WiSE technology introduces a leadless, versatile, and a physiologic approach to pacing the heart.
President & CEO
Chief Financial Officer
Chief Commercial Officer
The WiSE CRT System uses proprietary wireless technology to pace the left ventricle endocardially and deliver personalized pacing therapy to patients. Offering a versatile and leadless design, the WiSE System brings a more physiologic approach for physicians to treat patients.
The WiSE CRT System is designed to overcome the limitations of conventional CRT and is the only leadless left ventricular endocardial pacing (LVEP) device.
July 30, 2024 — Cardiac company EBR has released its Q2 2024 update and says regulatory activities are progressing to schedule for its WiSE Cardiac Resynchronization Therapy (CRT) system technology.
EBR is on track to submit the final module of its pre-market approval (PMA) application to the US FDA in Q3 2024 for WiSE, which uses proprietary wireless methods to provide pacing stimulation directly inside the heart’s left ventricle.
Recruiting Done Differently.
Improving lives by uniting great people with great companies.
We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!